Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype

Advances in Experimental Medicine and Biology

Volumn 779, Issue , 2013, Pages 91-143

  Yee, Nelson S ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Genetic targets; Pancreatic cancer; Personalized therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; CETUXIMAB; DALOTUZUMAB; ERLOTINIB; ETANERCEPT; EVEROLIMUS; EXATECAN; FLAVOPIRIDOL; GANETESPIB; GANITUMAB; ISIS 2503; K RAS PROTEIN; L 778123; LAPATINIB; NELFINAVIR; PANITUMUMAB; PERTUZUMAB; PIMASERTIB; PIOGLITAZONE; RUBITECAN; SELUMETINIB; TACEDINALINE; TEMSIROLIMUS; TIPIFARNIB; TIVANTINIB; TRASTUZUMAB; UNINDEXED DRUG; VORINOSTAT; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG WITHDRAWAL; GENE TARGETING; GENETIC DISORDER; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84873594890     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-6176-0_5     Document Type: Review

References (167)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011. CA Cancer J Clin. 2011;61:212-36.
2. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378:607-20.
3. Hong S-M, Park JY, Hruban RH, et al. Molecular signatures of pancreatic cancer. Arch Pathol Lab Med. 2011;135:716-27.
4. Hingorani SR. From inception to invasion: Modeling pathways to pancreatic cancer. In: Lowy AM et al., editors. Pancreatic cancer. New York: Springer; 2008. p. 159-79.
5. Lonardo E, Hermann PC, Heeschen C. Pancreatic cancer stem cells - update and future perspectives. Mol Oncol. 2010;4:431-42.
6. Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60:861-8.
7. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-72.
8. Yee NS, Furth EE, Pack M. Clinicopathologic and molecular features of pancreatic adenocarcinoma associated with Peutz-Jeghers syndrome. Cancer Biol Ther. 2003;2:38-47.
9. Koorstra J-BM, Hustinx SR, Offerhaus GJA, et al. Pancreatic carcinogenesis. Pancreatology. 2008;8:110-25.
10. Chun SG, Yee NS. Werner's syndrome as a hereditary risk factor for exocrine pancreatic cancer: Potential role of WRN in pancreatic tumorigenesis and patient-Tailored therapy. Cancer Biol Ther. 2010;10:430-7.
11. Hackel PO, Zwick E, Prenzel N, et al. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways. Curr Opin Cell Biol. 1999;11:184-9.
12. Sanvito F, Herrera PL, Huarte J, et al. TGF-beta 1 in fl uences the relative development of the exocrine and endocrine pancreas in vitro. Development. 1994;120:3451-62.
13. Cras-Meneur C, Elghazi L, Czernichow P, et al. Epidermal growth factor increases undifferentiated pancreatic embryonic cells in vitro: A balance between proliferation and differentiation. Diabetes. 2001;50:1571-9.
14. Korc M, Friess H, Yamanaka Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992;90:1352-60.
15. Lemoine NR, Hughes CM, Barton CM, et al. The epidermal growth factor receptor in human pancreatic cancer. J Pathol. 1992;166:7-12.
16. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13:565-9.
17. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol. 2004;22:2610-6.
18. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: A randomised, multicentre, phase II trial. Lancet Oncol. 2008;9:39-44.
19. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest oncology group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605-10.
20. Moore M, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6.
21. Beltran PJ, Mitchell P, Chung Y-A, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther. 2009;8:1095-105.
22. Birchmeier W, Brinkmann V, Niemann C, et al. Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. CIBA Found Symp. 1997;212:230-40.
23. Perugini RA, McDade TP, Vittimberga FJ, et al. The molecular and cellular biology of pancreatic cancer. Crit Rev Eukaryot Gene Expr. 1998;8:377-93.
24. Li C, Wu J-J, Hynes M. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011;141:2218-27.
25. Kim ST, Lim DH, Jang K-T, et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated withfirst-line gemcitabine-based chemotherapy. Mol Cancer Ther. 2011;10:1993-9.
26. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: Weaving a tumorigenic web. Nature Rev Cancer. 2011;11:761-74.
27. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549-54.
28. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2:344-58.
29. Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nature Rev Cancer. 2011;11:775-91.
30. Cohen SJ, Ho L, Ranganathan S, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003;21:1301-6.
31. Macdonald JS, McCoy S, Whitehead RP, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A southwest oncology group (SWOG 9924) study. Inves New Drug. 2005;23:485-7.
32. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-8.
33. Martin NE, Brunner TB, Kiel KD, et al. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res. 2004;10:5447-54.
34. Lobell RB, Liu D, Buser CA, et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-1. Mol Cancer Ther. 2002;1:747-58.
35. Green J, Lipton A. Anticaner properties of zoledronic acid. Cancer Invest. 2010;28:944-57.
36. Tassone P, Tagliaferri P, Viscomi C, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Brit J Cancer. 2003;88:1971-8.
37. Märten A, Lilienfeld-Toal M, Büchler MW, et al. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J Immunother. 2007;30:370-7
38. Gjertsen MK, Buanes T, Rosseland AR, et al. Intradermal ras peptide vaccination with granulocytemacrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. 2001;92:441-50.
39. Weden S, Klemp M, Gladhaug IP, et al. Long-Term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2011;128:1120-8.
40. Toubaji A, Achtar M, Provenzano M, et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother. 2008;57:1413-20.
41. Carbone DP, Ciernik IF, Kelley MJ, et al. Immunization with mutant p53- And K-ras-derived peptides in cancer patients: Immune response and clinical outcome. J Clin Oncol. 2005;23:5099-107.
42. Seufferlein T, Van Lint J, Liptay S, et al. Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology. 1999;116:1441-52.
43. Geary RS, Leeds JM, Henry SP, et al. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate Oligodeoxynucleotides. Anticancer Drug Des. 1997;12:383-93.
44. Alberts SR, Schroeder M, Erlichman C, et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A north central cancer treatment group phase II trial. J Clin Oncol. 2004;24:2944-50.
45. Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998;17:3351-62.
46. Etoh T, Himeno Y, Matsumoto T, et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res. 2003;9:1218-23.
47. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-Activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res. 2008;14:342-6.
48. LoRusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23:5281-93.
49. Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failedfirst-line gemcitabine therapy. Invest New Drug. 2011;30:1272-3.
50. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28:1075-83.
51. Semba C, Moriya T, Kimura W, et al. Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Pancreas. 2003;26:250-7.
52. Yamamoto S, Tomita Y, Hoshida Y, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:2846-50.
53. Stanger BZ, Stiles B, Lauwers GY, et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell. 2005;8:185-95.
54. Gupta AK, Cerniglia GJ, Mick R, et al. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both In vitro and In vivo. Cancer Res. 2005;65:8256-65.
55. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase 1 trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally, advanced pancreatic cancer. J Clin Oncol. 2008;26:2699-706.
56. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253-62.
57. Ito D, Fujimoto K, Mori T, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer. 2006;118:2337-43.
58. Javle MM, Shroff RT, Xiong H, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies. BMC Cancer. 2010;10:368.
59. Marks PA, Xu W-S. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009;107:600-8.
60. Zhou W, Liang IC, Yee NS. Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer. Cancer Biol Ther. 2011;11:659-70.
61. Kumagai T, Wakimoto N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer. 2007;121:656-65.
62. Arnold NB, Arkus N, Gunn J, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res. 2007;13:18-26.
63. Chun SG, Zhou W, Yee NS. Combined targeting of histone deacetylases and hedgehog signaling enhances cytotoxicity in pancreatic cancer. Cancer Biol Ther. 2009;8:1328-39.
64. Jackman M, Lindon C, Nigg EA, et al. Active cyclin B1-Cdk1first appears on centrosomes in prophase. Nat Cell Biol. 2003;5:143-8.
65. Gray Jr. PJ, Bearss DJ, Han H, et al. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther. 2004;3:641-6.
66. Weichert W, Schmidt M, Jacob J, et al. Overexpression of polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology. 2005;5:259-65.
67. Gumireddy K, Reddy MV, Cosenza SC, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005;7:275-86.
68. Attia S, Kolesar J, Mahoney MR, et al. A phase 2 consortium (P2C) trial of 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs. 2008;26:369-79.
69. Rosen ED, et al. PPAR g . A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001;276:37731-4.
70. Takeuchi Y, Takahashi M, Sakano K, et al. Suppression of N-nitrosobis(2-oxopropyl)amineinduced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-Activated receptor g . Carcinogenesis. 2007;28:1692-6.
71. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med. 2011;364:1817-25.
72. Clark JW. Rubitecan. Expert Opin Investig Drugs. 2006;15:71-9.
73. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006;24:4441-7.
74. Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007;6:918-25.
75. Wang LM, Ren DM. Flavopiridol, thefirst cyclin-dependent kinase inhibitor: Recent advances in combination chemotherapy. Mini Rev Med Chem. 2010;10:1058-70.
76. Carvajal RD, Tse A, Shah MA, et al. A phase II study of fl avopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology. 2009;9:404-9.
77. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16:1701-8.
78. Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF- A inhibitors. Expert Opin Drug Saf. 2012;11:1-5. Epub ahead of print.
79. Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 2001;163:71-81.
80. Yee NS. Zebrafish as a biological system for identifying and evaluating therapeutic targets and compounds. In: Han H, Grippo PJ, editors. Drug discovery in pancreatic cancer: Models and techniques. New York: Springer; 2010. p. 95-112.
81. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425:851-6.
82. Berman DM, Karhadkar S, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425:846-51.
83. Morton JP, Mongeau ME, Klimstra DS, et al. Sonnic hedgehog acts at multiple stages of pancreatic tumorigenesis. Proc Natl Acad Sci USA. 2007;104:5103-8.
84. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;36:1173-8.
85. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;36:1164-72.
86. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-61.
87. Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med. 2006;6:905-18.
88. Wang Z, Zhang Y, Li Y, et al. Down-regulation of notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006;5:483-93.
89. Wang Z, Banerjee S, Li Y, et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006;66:2778-84.
90. Puolakkainen PA, Brekken RA, Muneer S, et al. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res. 2004;2:215-24.
91. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol. 2011;29:4548-54.
92. Bloomston M, Zervos EE, Rosemurgy II AS, et al. Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials. Ann Surg Oncol. 2002;9:668-74.
93. Bramhall SR, Neoptolemos JP, Stamp GW, et al. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol. 1997;182:347-55.
94. Zervos EE, Norman JG, Gower WR, et al. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res. 1997;69:367-71.
95. Haq M, Shafii A, Zervos EE, et al. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. 2000;60:3207-11.
96. Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat asfirst-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol. 2001;19:3447-55.
97. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo asfirst line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87:161-7.
98. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3296-302.
99. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in in fl ammation, cancer, and development. Oncogene. 1999;18:7908-16.
100. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by Nonsteroidal antiin fl ammatory drugs. Cancer Res. 1999;59:4356-62.
101. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000;21:139-46.
102. Merati K, Said Siadaty M, Andea A, et al. Expression of in fl ammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Amer J Clin Oncol. 2001;24:447-52.
103. El-Rayes BF, Ali S, Sarkar FH, et al. Cyclooxygenase-2-dependent and - independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther. 2004;3:1421-6.
104. El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005;23:583-90.
105. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-40.
106. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol. 2010;28:3617-22.
107. Javle M, Yu J, Garrett C, et al. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study. Br J Cancer. 2009;100:1842-5.
108. Crane CH, Winter K, Regine WF, et al. Phase II study of Bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and Bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol. 2009;27:4096-102.
109. Ko AH, Dito E, Schillinger B, et al. A phase II study evaluating bevacizumab in combination withfixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: Is an anti-VEGF strategy still applicable? Invest New Drugs. 2008;26:463-71.
110. Ko AH, Venook AP, Bergsland EK, et al. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010;66:1051-7.
111. Howard OMZ, Ben-Baruch A, Oppenheim JJ. Chemokines: Progress toward identifying molecular targets for therapeutic agents. Trends Biotechnol. 1996;14:46-51.
112. Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: Regulation of expression and potential mechanisms of anti-malignant activity. Cancer Res. 2003;63:7451-61.
113. Hynes RO, Lively JC, McCarty JH, et al. The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb Symp Quant Biol. 2002;67:143-53.
114. Lee BH, Ruoslahti E. alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca2+/calmodulin-dependent protein kinase IV. J Cell Biochem. 2005;95:1214-23.
115. Mettouchi A, Meneguzzi G. Distinct roles of beta1 integrins during angiogenesis. Eur J Cell Biol. 2005;95:1214-23.
116. Bhaskar V, Zhang D, Fox M, et al. A function blocking anti-mouse integrin a 5 b 1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Translat Med. 2007;5:61.
117. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-8.
118. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002;62:819-26.
119. Pastan I, Hassan R, FitzGerald DJP, et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6:559-65.
120. Kreitman RJ, Hassan R, Fitzgerald DJ, et al. Phase I trial of continuous infusion of antimesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009;15:5274-9.
121. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer. 1988;57:239-46.
122. Southall PJ, Boxer GM, Bagshawe KD, et al. Immunohistological distribution of 5 T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61:89-95.
123. Borghaei H, Alpaugh K, Hedlund G, et al. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:4116-23.
124. Arnett SO, Teillaud J-L, Wurch T. IBC's 21st annual antibody engineering and 8th annual antibody therapeutics international conferences and 2010 annual meeting of the antibody society. mAbs. 2011;3:133-52.
125. Hammarstrom S. The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Seminars Cancer Biol. 1999;9:67-81.
126. Lutterbuese R, Raum T, Kischel R, et al. Potent control of tumor growth by CEA/CD3-bispecific single antibody constructs that are not competitively inhibited by soluble CEA. J Immunother. 2009;32:341-52.
127. Wente M, Jain A, Kono E, et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005;31:119-25.
128. Katari UL, Keiman JM, Worth AC, et al. Engineered T cells for pancreatic cancer treatment. HPB. 2011;13:643-50.
129. Brower V. Telomerase-based therapies emerging slowly. J Natl Cancer Inst. 2010;102:520-1.
130. Fonsatti E, Maio M, Altomonte M, et al. Biology and clinical applications of CD40 in cancer treatment. Semin Oncol. 2010;37:517-23.
131. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 Agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-6.
132. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734-6.
133. Salama AK, Hodi FS. Cytotoxic T-lymphocyte-Associated antigen-4. Clin Cancer Res. 2011;17:4622-8.
134. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828-33.
135. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006;27:195-201.
136. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151-7.
137. O'Brien P, O'Connor BF. Seprase: An overview of an important matrix serine protease. Biochim Biophys Acta. 2008;1784:1130-45.
138. Adams S, Miller GT, Jesson MI, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004;64:5471-80.
139. Spano JP, Chodkiewicz C, Maurel J, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study. Lancet. 2008;371:2101-8.
140. Kindler HL, Ioka T, Richel D, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomized phase 3 study. Lancet. 2011;12:256-62.
141. O'Reilly EM, Niedzwiecki D, Hall M, et al. A cancer and leukemia group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010;15:1310-9.
142. Richards DA, Kuefler PR, Becerra C, et al. Gemcitabine plus enzastaurin or single-Agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a phase II, randomized, noncomparative study. Invest New Drugs. 2011;29:144-53.
143. Yee NS. Brca2 deficiency and Trp53 deregulation in pancreatic cancer. Implications for therapeutic targeting. Cancer Biol Ther. 2011;11:969-73.
144. Skoulidis F, Cassidy LD, Pisupati V, et al. Germline Brca2 heterozygosity promotes Kras (G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell. 2010;18:499-509.
145. Rowley M, Ohashi A, Mondal G, et al. Inactivation of Brca2 promotes Trp53-Associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology. 2011;140:1303-13.
146. Feldmann G, Karikari C, dal Molin M, et al. Inactivation of Brca2 cooperates with Trp53 R172H to induce invasive pancreatic ductal adenocarcinomas in mice: A mouse model of familial pancreatic cancer. Cancer Biol Ther. 2011;11:959-68.
147. Sonnenblick A, Kadouri L, Appelbaum L, et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther. 2011;12:165-8.
148. Fogelman DR, Wolff RA, Kopetz S, et al. Evidence for the efficacy of iniparib, a PARP-1 inhibitor, in BRCA2-Associated pancreatic cancer. Anticancer Res. 2011;31:1417-20.
149. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011;10:3-8
150. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136:187-95.
151. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-7.
152. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-23.
153. Al-Aynati MM, Radulovich N, Riddell RH, et al. Epithelial-cadherin and beta-catenin expression changes in pancreatic intraepithelial neoplasia. Clin Cancer Res. 2004;10:1235-40.
154. Shah AN, Summy JM, Zhang J, et al. Development and characterization of gemcitabineresistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629-37.
155. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:5820-8.
156. Wellner U, Schubert J, Burk UC, et al. The EMT-Activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11:1487-95.
157. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500-3.
158. Gittes GK. Developmental biology of the pancreas: A comprehensive review. Dev Biol. 2009;326:4-35.
159. Tiso N, Moro E, Argenton F. Zebrafish pancreas development. Mol Cell Endocrinol. 2009;312:24-30.
160. Yee NS, Pack M. Zebrafish as a model for pancreatic cancer research. Methods Mol Med. 2004;103:273-98.
161. Yee NS, Lorent K, Pack M. Exocrine pancreas development in zebrafish. Dev Biol. 2005;284:84-101.
162. Yee NS, Gong W, Huang Y, et al. Mutation of RNA pol III subunit rpc2/polr3b leads to deficiency of subunit rpc11 and disrupts zebrafish digestive development. PLoS Biol. 2007;5:2484-92.
163. Yee NS, Zhou W, Liang IC. Transient receptor potential ion channel Trpm7 regulates exocrine pancreatic epithelial proliferation by Mg 2+ -sensitive Socs3a signaling in development and cancer. Dis Model Mech. 2011;4:240-54.
164. Yee NS, Zhou W, Lee M. Transient receptor potential channel TRPM8 is over-expressed and required for cellular proliferation of pancreatic adenocarcinoma. Cancer Lett. 2010;297:49-55.
165. Yee NS, Zhou LM, et al. Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma. Cancer Lett. 2012;318:99-105.
166. Yee NS, Brown RD, Lee MS, et al. TRPM8 ion channel is aberrantly expressed and required for preventing replicative senescence in pancreatic adenocarcinoma: Potential role of TRPM8 as a biomarker and target. Cancer Biol Ther. 2012;13:592-9.
167. Yee NS, Zhou W, Chun SG, et al. Targeting developmental regulators of zebrafish exocrine pancreas as a therapeutic approach in human pancreatic cancer. Biology Open 2012;1: 295-307.